HUP0002048A2 - CD40:CD154-kötődést akadályozó ágens alkalmazása terápiás proteinnel szembeni inhibitor-tünetegyüttes kezelésére alkalmas gyógyszer előállítására - Google Patents
CD40:CD154-kötődést akadályozó ágens alkalmazása terápiás proteinnel szembeni inhibitor-tünetegyüttes kezelésére alkalmas gyógyszer előállításáraInfo
- Publication number
- HUP0002048A2 HUP0002048A2 HU0002048A HUP0002048A HUP0002048A2 HU P0002048 A2 HUP0002048 A2 HU P0002048A2 HU 0002048 A HU0002048 A HU 0002048A HU P0002048 A HUP0002048 A HU P0002048A HU P0002048 A2 HUP0002048 A2 HU P0002048A2
- Authority
- HU
- Hungary
- Prior art keywords
- production
- syndrome
- binding
- agent
- blockade therapy
- Prior art date
Links
- 208000011580 syndromic disease Diseases 0.000 title abstract 4
- 229940121649 protein inhibitor Drugs 0.000 title abstract 2
- 239000012268 protein inhibitor Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 101150013553 CD40 gene Proteins 0.000 abstract 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 3
- 230000027455 binding Effects 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 239000002981 blocking agent Substances 0.000 abstract 1
- 230000009931 harmful effect Effects 0.000 abstract 1
- 230000016784 immunoglobulin production Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A találmány tárgya immunglobulin-termelést előidéző kostimulálószignál aktivált T-sejtekre történő továbbvitelét, közelebbről CD40 :CD154-kötődést akadályozó ágens, igen előnyösen az 5c8 elnevezésű,ATCC HB 10916 nyilvántartási számú ellenanyag antigénspecifikuskötődési sajátságaival rendelkező monoklonális ellenanyag alkalmazásaCD154-blokádterápiára alkalmas gyógyszer előállítása, közelebbről aCD40 : CD154-kötődést akadályozó ágens alkalmazása proteinnel szembeniinhibitor-tünetegyüttesben szenvedő egyedben vagy ilyen tünetegyütteskialakulása kockázatának kitett egyedben a tünetegyütteskialakulásának megelőzésére, késleltetésére, káros hatásainakszuppresszálására, súlyosságának enyhítésére alkalmas gyógyszerelőállítására. A találmány tárgya továbbá CD40 : CD154-kötődéstakadályozó ágens alkalmazása exogén proteinnel kezelt egyedben azexogén protein terápiás aktivitásának megőrzésére vagyvisszaállítására alkalmas gyógyszer előállítására. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5027697P | 1997-06-20 | 1997-06-20 | |
| PCT/US1998/012773 WO1998058672A1 (en) | 1997-06-20 | 1998-06-19 | Cd154 blockade therapy for therapeutic protein inhibitor syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0002048A2 true HUP0002048A2 (hu) | 2000-10-28 |
| HUP0002048A3 HUP0002048A3 (en) | 2002-09-30 |
Family
ID=21964347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0002048A HUP0002048A3 (en) | 1997-06-20 | 1998-06-19 | Cd154 blockade therapy for therapeutic protein inhibitor syndrome |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20020119151A1 (hu) |
| EP (1) | EP1034001B1 (hu) |
| JP (1) | JP2002504910A (hu) |
| KR (1) | KR100567998B1 (hu) |
| CN (2) | CN1651071A (hu) |
| AT (1) | ATE272408T1 (hu) |
| AU (1) | AU733062B2 (hu) |
| BG (1) | BG64436B1 (hu) |
| BR (1) | BR9810755A (hu) |
| CA (1) | CA2294138A1 (hu) |
| CZ (1) | CZ295805B6 (hu) |
| DE (1) | DE69825473T2 (hu) |
| EA (1) | EA002512B1 (hu) |
| EE (1) | EE9900587A (hu) |
| ES (1) | ES2226152T3 (hu) |
| HK (1) | HK1031825A1 (hu) |
| HU (1) | HUP0002048A3 (hu) |
| IL (1) | IL133305A0 (hu) |
| IS (1) | IS2097B (hu) |
| NO (1) | NO996274L (hu) |
| NZ (1) | NZ502051A (hu) |
| PT (1) | PT1034001E (hu) |
| SK (1) | SK285962B6 (hu) |
| TR (1) | TR199903141T2 (hu) |
| WO (1) | WO1998058672A1 (hu) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2343916A1 (en) * | 1998-09-21 | 2000-03-30 | Genetics Institute, Inc. | Methods of downmodulating the immune response to therapeutic proteins |
| AU2001251612A1 (en) | 2000-04-14 | 2001-10-30 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
| CN1441675A (zh) | 2000-05-12 | 2003-09-10 | 贝斯以色列护理医疗中心有限公司 | 免疫抑制组合物及方法 |
| IES20030305A2 (en) * | 2002-04-23 | 2003-10-29 | Desmond Joseph Fitzgerald | Inhibition of platelet aggregation |
| DE602004029252D1 (de) * | 2003-06-13 | 2010-11-04 | Biogen Idec Inc | Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen |
| ES2353222T3 (es) * | 2003-06-13 | 2011-02-28 | Biogen Idec Ma Inc. | Anticuerpos anti-cd154 (ligando cd40) aglicosilados y usos de los mismos. |
| AU2011224032B2 (en) * | 2003-06-13 | 2013-01-31 | Biogen Ma Inc. | Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof |
| ATE473016T1 (de) | 2003-11-04 | 2010-07-15 | Novartis Vaccines & Diagnostic | Verfahren zur behandlung von krebs mit expression des cd40-antigens |
| GEP20105059B (en) | 2004-07-26 | 2010-08-10 | Biogen Idec Inc | Anti-cd154 antibodies |
| WO2006017574A1 (en) * | 2004-08-03 | 2006-02-16 | Mayo Foundation For Medical Education And Research | Improving treatments |
| ES2429564T3 (es) | 2005-05-18 | 2013-11-15 | Novartis Ag | Procedimientos para el diagnóstico y tratamiento de enfermedades que tienen un componente autoinmune y/o inflamatorio |
| MX2008013508A (es) | 2006-04-21 | 2008-10-31 | Novartis Ag | Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40. |
| US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| US9447156B2 (en) | 2011-05-17 | 2016-09-20 | St. Jude Children's Research Hospital | Methods and compositions for inhibiting neddylation of proteins |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| ZA946765B (en) * | 1993-09-02 | 1996-02-15 | Dartmouth College | Methods of prolonged suppression of humoral immunity |
| US5872154A (en) * | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
| DE69837322T2 (de) * | 1997-01-10 | 2007-11-22 | Biogen Idec Ma Inc., Cambridge | Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln |
-
1998
- 1998-06-19 EP EP98931391A patent/EP1034001B1/en not_active Expired - Lifetime
- 1998-06-19 NZ NZ502051A patent/NZ502051A/en unknown
- 1998-06-19 PT PT98931391T patent/PT1034001E/pt unknown
- 1998-06-19 WO PCT/US1998/012773 patent/WO1998058672A1/en active IP Right Grant
- 1998-06-19 TR TR1999/03141T patent/TR199903141T2/xx unknown
- 1998-06-19 HU HU0002048A patent/HUP0002048A3/hu unknown
- 1998-06-19 AT AT98931391T patent/ATE272408T1/de not_active IP Right Cessation
- 1998-06-19 JP JP50339199A patent/JP2002504910A/ja not_active Ceased
- 1998-06-19 ES ES98931391T patent/ES2226152T3/es not_active Expired - Lifetime
- 1998-06-19 EA EA200000059A patent/EA002512B1/ru not_active IP Right Cessation
- 1998-06-19 CN CNA2004100978650A patent/CN1651071A/zh active Pending
- 1998-06-19 EE EEP199900587A patent/EE9900587A/xx unknown
- 1998-06-19 SK SK1803-99A patent/SK285962B6/sk unknown
- 1998-06-19 CN CN98806403A patent/CN1261285A/zh active Pending
- 1998-06-19 IL IL13330598A patent/IL133305A0/xx unknown
- 1998-06-19 DE DE69825473T patent/DE69825473T2/de not_active Expired - Fee Related
- 1998-06-19 CA CA002294138A patent/CA2294138A1/en not_active Abandoned
- 1998-06-19 BR BR9810755-0A patent/BR9810755A/pt not_active Application Discontinuation
- 1998-06-19 AU AU81536/98A patent/AU733062B2/en not_active Ceased
- 1998-06-19 KR KR1019997011990A patent/KR100567998B1/ko not_active IP Right Cessation
- 1998-06-19 CZ CZ19994588A patent/CZ295805B6/cs not_active IP Right Cessation
-
1999
- 1999-11-26 IS IS5274A patent/IS2097B/is unknown
- 1999-12-17 NO NO996274A patent/NO996274L/no not_active Application Discontinuation
-
2000
- 2000-01-18 BG BG104092A patent/BG64436B1/bg unknown
-
2001
- 2001-02-14 HK HK01101074A patent/HK1031825A1/xx not_active IP Right Cessation
-
2002
- 2002-04-19 US US10/127,228 patent/US20020119151A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0002048A2 (hu) | CD40:CD154-kötődést akadályozó ágens alkalmazása terápiás proteinnel szembeni inhibitor-tünetegyüttes kezelésére alkalmas gyógyszer előállítására | |
| HUP0002062A2 (hu) | Eljárás metabolikus csontbetegségek diagnózisára | |
| Markvardsen et al. | Subcutaneous immunoglobulin as first‐line therapy in treatment‐naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study | |
| Arredouani et al. | Haptoglobin directly affects T cells and suppresses T helper cell type 2 cytokine release | |
| Patel et al. | Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis | |
| Pichler | Adverse side‐effects to biological agents | |
| Nishimoto et al. | Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: a multicenter, double‐blind, placebo‐controlled trial | |
| DK0942740T3 (da) | Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme | |
| Hahn et al. | Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus | |
| NO331072B1 (no) | Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme. | |
| Marker et al. | Successful immunoapheresis of bullous autoimmune diseases: pemphigus vulgaris and pemphigoid gestationis | |
| Al Ghazal et al. | Therapy of pyoderma gangrenosum in Germany: results of a survey among wound experts | |
| Fox et al. | Rituximab for adolescents with haemophilia and high titre inhibitors | |
| Puppo et al. | Emerging biologic drugs for the treatment of rheumatoid arthritis | |
| Zhou et al. | A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b | |
| Luross et al. | Escherichia coli heat‐labile enterotoxin B subunit prevents autoimmune arthritis through induction of regulatory CD4+ T cells | |
| Uzonna et al. | Anti‐IL‐4 antibody therapy causes regression of chronic lesions caused by medium‐dose Leishmania major infection in BALB/c mice | |
| JPH09510952A (ja) | 自己免疫疾患および炎症性疾患の治療 | |
| Mauri et al. | Down‐regulation of Th1‐mediated pathology in experimental arthritis by stimulation of the Th2 arm of the immune response | |
| Poddighe et al. | Conventional and novel therapeutic options in children with familial Mediterranean fever: A rare autoinflammatory disease | |
| Quinti et al. | Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration | |
| Hohwy et al. | Alemtuzumab‐induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment‐resistant B‐cell chronic lymphocytic leukaemia | |
| Berenson et al. | A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma | |
| Moschovi et al. | Rituximab in the treatment of high responding inhibitors in severe haemophilia A | |
| Noda et al. | Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community‐based hospital |